Nature's medicines: Traditional knowledge and intellectual property management. Case studies from the National Institutes of Health (NIH), USA

Current Drug Discovery Technologies

Volumn 2, Issue 4, 2005, Pages 203-219

  Gupta, Ranjan ^a   Gabrielsen, Bjarne ^b   Ferguson, Steven M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; CALANOLIDE A; CALANOLIDE B; DIGITALIS; FLAVONOID; GLYCOSIDE; HEMIASTERLIN; NATURAL PRODUCT; NEW DRUG; PACLITAXEL; PENICILLIN DERIVATIVE; PLANT EXTRACT; RESERPINE; STREPTOMYCIN; TALTOBULIN; TERPENOID DERIVATIVE; UNCLASSIFIED DRUG; VACCINE;

CALOPHYLLUM; COMBINATORIAL CHEMISTRY; CULTURAL ANTHROPOLOGY; DRUG IDENTIFICATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; GENOMICS; HIGH THROUGHPUT SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFECTION; LAW; MEDICINAL PLANT; MULTIDRUG RESISTANCE; NONHUMAN; PATENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UNITED STATES;

ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; DRUG DESIGN; HUMANS; INTELLECTUAL PROPERTY; KNOWLEDGE; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES;

EID: 31544445217     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016305775202937     Document Type: Review

References (35)

1. Cragg G.M., Newman D.J.: Drugs from nature: past achievements, future prospects. In Advances in Phytomedicine: Ethnomedicine and Drug Discovery; Iwu M.M. and Wootton, J.C. Eds.; Elsevier: Amsterdam, Vol. 1, pp. 23-37, (2002).
2. Cragg G.M., Boyd M.R., Grever M.R., Mays T.M., Newman D.J., Schepartz S.A.: Natural product, drug discovery and development at the National Cancer Institute: Policies for International Collaboration and Compensation. In Conservation of Plant Genes II: Utilization of Ancient and Modern DNA, Monogr. Syst. Bot. Missouri Botanical Garden, Adams R.P., Miller J.S., Goldberg E.M. and Adams J.E. Eds.; pp. 221-232, (1994).
3. Duke J.A. CRC Handbook of Medicinal Herbs. CRC Press, Inc.: Boca Raton, FL, (1985).
4. Duke J.A. Medicinal Plants of the Bible. Tradco-Medic Books, Conch Magazine, Ltd., Publishers: New York, (1983).
5. Newman D.J., Cragg G.M., Snader K.M.: Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66, 1022, (2003).
6. Lesney M.S.: Nature's Pharmaceuticals: Natural Products from Plants Remain at the Core of Modern Medicinal Chemistry. TCAW 13(7), 26, (2004).
7. National Cooperative Biodiversity Groups; Hallock Y. F. and Cragg G. M. Guest Eds.; Taylor & Francis Ltd., The Netherlands; Pharm. Biol. Vol. 41 Supplement (2003).
8. Koehn F. E., Carter G. T.: The Evolving Role of Natural Products in Drug Discovery. Nat. Rev. Drug Discov. 4, 206, (2005).
9. Rogers D.T., Falcone D.L., Littleton J.M.: A Functional Genomics Study for Plant Drug Discovery. PharmaGenomics 3(6), 26, (2003).
10. Bioprospecting: Experiences of Diversa Corporation, Kina Biotech and INBio, IP Strategy Today No.11, 2004.
11. Sampath P.G.: Regulating Bioprospecting: Institutions for Drug Research Access and Benefit-Sharing. Policy Brief No. 1, The United Nations University, (2005).
12. Cragg G., Suffness M.: Metabolism of Plant-Derived Anticancer Agents. In Intracellular Messengers; Taylor C.W. Ed.; Pergamon Press Ltd., U.K., Chapter 8 (1993).
13. Cragg G.M., Newman D.J.: Plants as a source of anti-cancer agents. J. Ethnopharmacol. 100(1-2), 72 (2005).
14. Hallock Y.F., Cragg G.M.: National Cooperative Drug Discovery Groups (NCDDGs): A Successful Model for Public Private Partnerships in Cancer Drug Discovery. Pharm. Biol. 41(Suppl.), 78, (2003).
15. Grifo, F.T.: Chemical Prospecting: An Overview of the International Cooperative Biodiversity Groups Program. In Emerging Connections: Biodiversity, Biotechnology and Sustainable Development in Health and Agriculture, Feinsilver, J. Ed.; Proceedings of the Pan American Health Organization Conference, San Jose, Costa Rica, (1994).
16. Report of a Special Panel of Experts on the International Cooperative Biodiversity Groups (ICBG), (1997).
17. Rosenthal J.P. Equitable Sharing of Biodiversity Benefits: Agreements on Genetic Resources. In Investing in Biological Diversity: Proceedings of the Cairns Conference, OECD (1997).
18. Rosenthal J., Beck D., Bhat A., Biswas J., Brady L., Bridbord K., Collins S., Cragg G., et al.: Combining high risk science with ambitious social and economic goals. Pharm. Biol. 37(Suppl.), 6, (1999).
19. Drug Discovery, Economic Development and Conservation: The International Cooperative Biodiversity Groups; Rosenthal J. P. Guest Ed.; Swets & Zeitlinger b.v., The Netherlands; Pharm. Biol. Vol. 37 Supplement, (1999).
20. Rosenthal J. P.: Politics, culture and governance in the development of prior informed consent in indigenous communities. Curr. Anthropol. in press, (2005).
21. Koo B., Nottenburg C., Pardey P.G.: Plants and Intellectual Property: An International Appraisal. Science, 306, 1295, (2004).
22. Miller J.A.: Impact of the Convention on Biological Diversity: The Lessons of Ten Years of Experience with Models for Equitable Sharing of Benefits. Discussion paper, Biodiversity and Biotechnology and the Protection of Traditional Knowledge Conference, April 4-6, 2003, Washington University School of Law, St. Louis, Missouri, (2003).
23. Sampath P.G.: Defining Intellectual Property Right on Traditional Medicine Knowledge: A Process-Oriented Perspective. Discussion Paper, The United Nations University, Institute for New Technologies (UNU/INTECH), (2002).
24. SBIR and STTR Success Story for Sarawak MediChem Pharmaceuticals, Inc., NIH SBIR webpage [http://grants1.nih.gov/grants/funding/sbir_successes/154.htm]
25. ten Kate K., Wells A.: Access and benefit-sharing policies of the United States National Cancer Institute: A comparative account of the discovery and development of the drugs Calanolide and Topotecan. In Access to Genetic Resources and Benefit-Sharing Case Studies, Convention on Biological Diversity, Royal Botanic Gardens, Kew, (1998). [http://www.biodiv.org/programmes/socioeco/ benefit/case-studies.asp].
26. Ireland C.M., Aalbersberg W., Andersen R.J., Ayral-Kaloustian S., Berlinck R.G.S., Bernan V., Carter G., Churchill A.C.L., et al.: Anticancer Agents from Unique Natural Product Sources. Pharm. Biol. 41(Suppl.), 15, (2003).
27. Loganzo F., Dicafani C.M., Annable T., Beyer C., Musto S., Hari M., Tan X., Hardy C., et al.: HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein mediated resistance in vitro and in vivo. Cancer Res. 63, 1838, (2003).
28. Hallowell C.: Heroes of Medicine: The Plant Hunter. Time Magazine (online), (2005).
29. Korin Y.D., Brooks D.G., Brown S., Korotzer A., Zack J.A.: Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus Latency. J. Virol. 76(16), 8118, (2002).
30. Microbial Source for Anti-HIV Compound Prostratin. Press Release, Apia, Samoa, (2004).
31. Cunningham A.B.: Ethics, Biodiversity, and New Natural Products Development: Report of WWF/UNESCO/Kew "People and Plants" Initiative. In People and Plants Online, Royal Botanic Gardens, Kew B, Lindsay Ed.; WWF International Publications Unit, (1993).
32. Gollin M.: Answering the Call: Public Interest Intellectual Property Advisors. Discussion paper, Biodiversity and Biotechnology and the Protection of Traditional Knowledge Conference, April 4-6, 2003, Washington University School of Law, St. Louis, Missouri, (2003).
33. King S.R.: Commentary On Biodiversity, Biotechnology and the Protection of Traditional Knowledge Conference April 4-6, 2003: Session # 4 Ethnobotany and Bioprospecting-Thinking Globally, Acting Locally. Washington University School of Law, St. Louis, Missouri, (2003).
34. WIPO Portal of Online Databases and Registries of Traditional Knowledge and Genetic Resources [http://www.wipo.int/tk/en/databases/tkportal/]
35. NAPRALERT, University of Illinois at Chicago [http://www.ag.uiuc.edu/ ∼ffh/napra.html]